

**Amendments to the Claims**

Please amend Claims 2-10. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Original) An antitumor agent comprising an antitumor component blended with hydroxyapatite.
2. (Currently Amended) The antitumor agent of claim 1, wherein the ~~method of administering a hydroxyapatite-blended antitumor agent~~ is administered includes administration by one or more routes selected from the group consisting of injection, and/or infusion, and/or oral administration.
3. (Currently Amended) The antitumor agent of claim 1 ~~and claim 2~~, wherein the antitumor component is an alkylating agent, an antimetabolite, an antitumor antibiotic, a plant preparation, a hormone preparation, an immunotherapeutic agent, a platinum preparation, or an antitumor agent not classified as above.
4. (Currently Amended) The antitumor agent of ~~claims 1 to claim 3~~ claim 3, wherein the antitumor component is cyclophosphamide, fluorouracil, bleomycin hydrochloride, bleomycin, bleomycin sulfate, etoposide, vincristine sulfate, interferon- $\beta$ , cisplatin, carboplatin, nedaplatin, mitomycin C, doxorubicin, nimustine hydrochloride, fluorouracil, carboquone, paclitaxel, melphalan, vinblastine sulfate, dacarbazine, ifosfamide, thiotepa, vinorelbine tartrate, vinorelbine, neocarzinostatin, tegafur, methotrexate, vindesine sulfate, goserelin acetate, sobuzoxane, tretinoin, estramustine sodium phosphate, toremifene citrate, flutamide, hydroxycarbamide, cytarabine ocfosfate, mercaptopurine, tamoxifen citrate, doxifluridine, busulphan, gefinitib, imatinib mesilate, oxaliplatin, UFT, carmofur, aceglatone, anastrozole, ubenimex, fadrozole hydrochloride hydrate, procarbazine hydrochloride, or bicalutamide.
5. (Currently Amended) The antitumor agent of claim[[s]] 1 ~~to 4~~, comprising hydroxyapatite with a maximum particle size of 1  $\mu\text{m}$  or less.

6. (Currently Amended) The antitumor agent of claim[[s]] 1 ~~to 4~~, comprising hydroxyapatite with a maximum particle size of 0.1  $\mu\text{m}$  or less.
7. (Currently Amended) The antitumor agent of ~~claims 1 to 4~~ claim 2, comprising hydroxyapatite with a maximum particle size of 5  $\mu\text{m}$  or less, wherein the antitumor agent is for oral administration.
8. (Currently Amended) The antitumor agent of ~~claims 1 to 4~~ claim 2, comprising hydroxyapatite with a maximum particle size of 0.5  $\mu\text{m}$  or less, wherein the antitumor agent is for oral administration.
9. (Currently Amended) The antitumor agent of claim[[s]] 1 ~~to 4~~, wherein the amount of hydroxyapatite blended is 0.1 to 1000% of the antitumor component.
10. (Currently Amended) The antitumor agent of claim[[s]] 1 ~~to 4~~, comprising pulverizing the mixture of antitumor component and hydroxyapatite.